BioAtla Receives FDA Approval to Begin Trials of BA3361, a Conditionally Active Biologic (CAB) Targeting Nectin-4 in Various Cancers.

Mediar Initiates Clinical Stage for Its Unique Fibrosis Collection with Initial Group Treatment in Phase 1 Study of MTX-463, and Forms a Clinical Advisory Committee.

GIBF commits $10 million in funding to Nectin Therapeutics for the development of innovative first-in-class immunotherapies and antibody-drug conjugates.

Edgewise Therapeutics has administered the initial dose to a participant in the Phase 2 CIRRUS-HCM study, evaluating EDG-7500 in patients with Obstructive Hypertrophic Cardiomyopathy (HCM).

Fate Therapeutics Reveals FT522 Early-Stage Data on Autoimmune Disorders in a New Abstract at the ASGCT Annual Conference.

HanAll Biopharma Launches Phase III Double-Blind, Placebo-Controlled VELOS-4 Study to Assess Tanfanercept in Treating Dry Eye Syndrome.

TAR-200 treatment alone achieves over 80% total remission in high-risk patients with non-muscle-invasive bladder cancer.

Guangzhou Bio-gene Technologies has launched the first phase of clinical trials for its CAR-T cell therapy BG1805, which targets CLL-1.

selectION, Inc. has shared encouraging outcomes from its initial human Phase 1b study concerning its primary drug, si-544, targeted at individuals with atopic dermatitis.

AriBio Granted EMA Approval for Phase 3 Trials of AR1001 in Alzheimer’s Treatment (POLARIS-AD).

Ractigen Therapeutics has received FDA clearance for RAG-01, a pioneering saRNA treatment for NMIBC that does not respond to BCG.

U.S. FDA Sanctions Single-Dose Gene Treatment BEQVEZ™ (fidanacogene elaparvovec-dzkt) by Pfizer for Adult Hemophilia B Patients.